Page 82 - AN-1-2

Advanced Neurology NMDA receptors in neuropsychiatric diseases

huntingtin. Nat Med, 15: 1407–1413. https://doi.org/1017/S1461145708008985
https://doi.org/1038/nm.2056 249. Jiang A, Su P, Li S, et al., 2021, Disrupting the alpha7nAChR-
NR2A protein complex exerts antidepressant-like effects.
239. GBD 2015 Disease and Injury Incidence and Prevalence Mol Brain, 14: 107.
Collaborators, 2016, Global, regional, and national
incidence, prevalence, and years lived with disability https://doi.org/1186/s13041-021-00817-3
for 310 diseases and injuries, 1990-2015: A systematic 250. Zanos P, Moaddel R, Morris PJ, et al., 2016, NMDAR
analysis for the global burden of disease study 2015. Lancet, inhibition-independent antidepressant actions of ketamine
388: 1545–1602. metabolites. Nature, 533: 481–486.
https://doi.org/1016/S0140-6736(16)31678-6 https://doi.org/1038/nature17998
240. Tiller JW, 2013, Depression and anxiety. Med J Aust, 199: 251. Bullock R, Zauner A, Woodward JJ, et al., 1998, Factors
S28–S31. affecting excitatory amino acid release following severe
https://doi.org/5694/mja12.10628 human head injury. J Neurosurg, 89: 507–518.
241. Diefenbach GJ, McCarthy-Larzelere ME, Williamson DA, https://doi.org/3171/jns.1998.89.4.0507
et al., 2001, Anxiety, depression, and the content of worries. 252. Simon RP, Swan JH, Griffiths T, et al., 1984, Blockade
Depression Anxiety, 14: 247–250. of N-methyl-D-aspartate receptors may protect against
https://doi.org/1002/da.1075 ischemic damage in the brain. Science, 226: 850–852.
242. Feifel D, 2016, Breaking sad: Unleashing the breakthrough https://doi.org/1126/science.6093256
potential of Ketamine’s rapid antidepressant effects. Drug 253. Chen MH, Bullock R, Graham DI, et al., 1991, Ischemic
Dev Res, 77: 489–494. neuronal damage after acute subdural hematoma in the
https://doi.org/1002/ddr.21347 rat: effects of pretreatment with a glutamate antagonist.
J Neurosurg, 74: 944–950.
243. Fukumoto K, Toki H, Iijima M, et al., 2017, Antidepressant
potential of (R)-ketamine in rodent models: Comparison https://doi.org/3171/jns.1991.74.6.0944
with (S)-ketamine. J Pharmacol Exp Ther, 361: 9–16. 254. Margaill I, Parmentier S, Callebert J, et al., 1996, Short
https://doi.org/1124/jpet.116.239228 therapeutic window for MK-801 in transient focal cerebral
ischemia in normotensive rats. J Cerebral Blood Flow Metab,
244. Ionescu DF, Fu DJ, Qiu X, et al., 2021, Esketamine nasal spray 16: 107–113.
for rapid reduction of depressive symptoms in patients with
major depressive disorder who have active suicide ideation https://doi.org/1097/00004647-199601000-00013
with intent: results of a phase 3, double-blind, randomized 255. Liu Y, Wong TP, Aarts M, et al., 2007, NMDA receptor
study (ASPIRE II). Int J Neuropsychopharmacol, 24: 22–31. subunits have differential roles in mediating excitotoxic
https://doi.org/1093/ijnp/pyaa068 neuronal death both in vitro and in vivo. J Neurosci,
27: 2846–2857.
245. Pittenger C, Sanacora G, Krystal JH, 2007, The NMDA
receptor as a therapeutic target in major depressive disorder. https://doi.org/1523/JNEUROSCI.0116-07.2007
CNS Neurol Disord Drug Targets, 6: 101–115. 256. Chen M, Lu TJ, Chen XJ, et al., 2008, Differential roles of
https://doi.org/2174/187152707780363267 NMDA receptor subtypes in ischemic neuronal cell death
and ischemic tolerance. Stroke, 39: 3042–3048.
246. Feyissa AM, Chandran A, Stockmeier CA, et al., 2009,
Reduced levels of NR2A and NR2B subunits of NMDA https://doi.org/1161/STROKEAHA.108.521898
receptor and PSD-95 in the prefrontal cortex in major 257. Yang Y, Li Q, Yang T, et al., 2003, Reduced brain infarct
depression. Prog Neuropsychopharmacol Biol Psychiatry, volume and improved neurological outcome by inhibition
33: 70–75. of the NR2B subunit of NMDA receptors by using
https://doi.org/1016/j.pnpbp.2008.10.005 CP101,606-27 alone and in combination with rt-PA in
a thromboembolic stroke model in rats. J Neurosurg,
247. Karolewicz B, Stockmeier CA, Ordway GA, 2005, Elevated 98: 397–403.
levels of the NR2C subunit of the NMDA receptor in the
locus coeruleus in depression. Neuropsychopharmacology, https://doi.org/3171/jns.2003.98.2.0397
30: 1557–1567. 258. Aarts M, Liu Y, Liu L, et al., 2002, Treatment of ischemic
brain damage by perturbing NMDA receptor- PSD-95
https://doi.org/1038/sj.npp.1300781
protein interactions. Science, 298: 846–850.
248. Karolewicz B, Stockmeier CA, Ordway GA, 2009, Elevated
levels of NR2A and PSD-95 in the lateral amygdala in https://doi.org/1126/science.1072873
depression. Int J Neuropsychopharmacol, 12: 143–153. 259. Cook DJ, Teves L, Tymianski M, 2012, A translational

Volume 1 Issue 2 (2022) 26 https://doi.org/10.36922/an.v1i2.148